Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Operating Margin (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Operating Margin for 14 consecutive years, with 2536.23% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 78355.0% year-over-year to 2536.23%, compared with a TTM value of 2222.45% through Dec 2025, down 67982.0%, and an annual FY2025 reading of 2222.45%, down 67982.0% over the prior year.
  • Operating Margin was 2536.23% for Q4 2025 at Fate Therapeutics, down from 1995.12% in the prior quarter.
  • Across five years, Operating Margin topped out at 48.48% in Q1 2023 and bottomed at 6705.79% in Q2 2023.
  • Average Operating Margin over 5 years is 1636.75%, with a median of 1184.8% recorded in 2024.
  • The sharpest move saw Operating Margin crashed -625774bps in 2023, then skyrocketed 604006bps in 2024.
  • Year by year, Operating Margin stood at 406.48% in 2021, then soared by 64bps to 145.23% in 2022, then tumbled by -1875bps to 2868.44% in 2023, then decreased by -16bps to 3319.78% in 2024, then rose by 24bps to 2536.23% in 2025.
  • Business Quant data shows Operating Margin for FATE at 2536.23% in Q4 2025, 1995.12% in Q3 2025, and 1938.54% in Q2 2025.